🔴 Outlook Therapeutics is trading 6% down today as biotech weakness may have contributed

Outlook Therapeutics is trading at $0.53, down -5.91%, with biotech-sector weakness a possible contributing factor.

• No clear company-specific announcement explaining the October 14 decline surfaced in the available news search; the latest identified company news was its chief commercial officer appointment ahead of the planned LYTENAVA launch.
• XBI was down 2.01% during the session, while broader index moves were mixed and smaller. This supports a sector explanation, not a confirmed company-specific cause.